XERIS Pharmaceuticals
Re: XERIS Pharmaceuticals
Xeris lijkt me een overnameprooi van big pharma
besportie liked last!
Laatste artikelen op Beursig.com
Beleggen in bitcoin en ethereum op Euronext beurs
Wild west taferelen bij aandelen, crypto valuta en ...
Volg Beursig.com
Re: XERIS Pharmaceuticals
CHICAGO, April 18, 2023--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the U.S. Patent and Trademark Office has issued US Patent Number 11,590,205, entitled ‘METHODS FOR PRODUCING STABLE THERAPEUTIC GLUCAGON FORMULATIONS IN APROTIC POLAR SOLVENTS.’ The claims in this newly issued patent cover certain pharmaceutical formulations in Xeris’ Gvoke® product line, methods of use of such formulations in treating hypoglycemia, and methods of manufacturing the therapeutic formulations.
"Xeris’ strategy is to patent early and often, including through a castle/moat approach that has led to numerous filings both at the platform and product levels. The addition of this new patent further strengthens our intellectual property position in the XeriSol™ platform portion of our portfolio and has claims that will cover the Gvoke formulation, which is in all our currently marketed Gvoke products," said Paul R. Edick, Xeris’ Chairman and CEO.
The Xeris patent portfolio consists of 178 total patents globally, of which 33 are U.S. issued; 128 patent applications pending globally, of which 21 are pending in the U.S.; and 60 patents pertaining to its technology platform. Xeris’ XeriSol patent portfolio includes patents and applications directed to this platform formulation technology, commercial and pipeline pharmaceutical product formulations, and therapeutic methods using such formulations to treat a variety of human diseases and disorders. All patents are owned by Xeris Biopharma subsidiaries.
believer liked last!
"Xeris’ strategy is to patent early and often, including through a castle/moat approach that has led to numerous filings both at the platform and product levels. The addition of this new patent further strengthens our intellectual property position in the XeriSol™ platform portion of our portfolio and has claims that will cover the Gvoke formulation, which is in all our currently marketed Gvoke products," said Paul R. Edick, Xeris’ Chairman and CEO.
The Xeris patent portfolio consists of 178 total patents globally, of which 33 are U.S. issued; 128 patent applications pending globally, of which 21 are pending in the U.S.; and 60 patents pertaining to its technology platform. Xeris’ XeriSol patent portfolio includes patents and applications directed to this platform formulation technology, commercial and pipeline pharmaceutical product formulations, and therapeutic methods using such formulations to treat a variety of human diseases and disorders. All patents are owned by Xeris Biopharma subsidiaries.
Re: XERIS Pharmaceuticals
Plus 8% in voorbeurs
Re: XERIS Pharmaceuticals
besportie liked last!
Re: XERIS Pharmaceuticals
CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its first quarter 2023 financial results before the open of the U.S. financial markets on Tuesday, May 9, 2023. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company’s financial and operational results.
Re: XERIS Pharmaceuticals
Samenvatting cijfers:
Achieved first quarter total revenue of $33.2M representing 50% growth compared to Q1 2022
Ended Q1 2023 with $95.1M in cash, cash equivalents, and short-term investments
Affirms 2023 guidance: total revenue of $135M-$165M; cash utilization from operating activities of $57M-$77M; year-end cash, cash equivalents, and short-term investments of $45M-$65M
Announced research collaboration and option agreement with Regeneron for XeriJect® formulation®
Ricki Fairley joined Board of Directors
Hosting conference call and webcast today at 8:30 a.m. ET
CHICAGO, May 09, 2023--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the first quarter ended March 31, 2023, and other corporate highlights.
"We had a very strong start to 2023 with record total revenue, strong underlying patient demand in all three commercial products, and the addition of another XeriJect collaboration," said Paul R. Edick, Chairman and CEO of Xeris Biopharma. "With continued steady and strong execution, we believe that we can achieve our 2023 revenue and year-end cash guidance and achieve cash flow breakeven in the fourth quarter this year."
Achieved first quarter total revenue of $33.2M representing 50% growth compared to Q1 2022
Ended Q1 2023 with $95.1M in cash, cash equivalents, and short-term investments
Affirms 2023 guidance: total revenue of $135M-$165M; cash utilization from operating activities of $57M-$77M; year-end cash, cash equivalents, and short-term investments of $45M-$65M
Announced research collaboration and option agreement with Regeneron for XeriJect® formulation®
Ricki Fairley joined Board of Directors
Hosting conference call and webcast today at 8:30 a.m. ET
CHICAGO, May 09, 2023--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the first quarter ended March 31, 2023, and other corporate highlights.
"We had a very strong start to 2023 with record total revenue, strong underlying patient demand in all three commercial products, and the addition of another XeriJect collaboration," said Paul R. Edick, Chairman and CEO of Xeris Biopharma. "With continued steady and strong execution, we believe that we can achieve our 2023 revenue and year-end cash guidance and achieve cash flow breakeven in the fourth quarter this year."
Re: XERIS Pharmaceuticals
https://finance.yahoo.com/news/presiden ... 32819.html
Na hoog volume donderdag en vrijdag vandaag na 10min al 400k verhandeld.
Naast 3 producten op de markt, ook deals met Regeneron en Horizon.
Na hoog volume donderdag en vrijdag vandaag na 10min al 400k verhandeld.
Naast 3 producten op de markt, ook deals met Regeneron en Horizon.
